2023
Imaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original Research
2018
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.
Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. Radiology 2018, 287: 667-675. PMID: 29388903, PMCID: PMC5929369, DOI: 10.1148/radiol.2017162610.Peer-Reviewed Original ResearchConceptsPositron emission tomographyDifferent cancer typesCancer typesAcid levelsFisher's exact testAmino acid levelsInvestigational new drug applicationGlutamine metabolismInstitutional review boardFluorodeoxyglucose avidityAdult patientsIntravenous bolusAcute fastingAggressive tumorsClinical safetyPotential tumor biomarkerPET scansPatientsExact testHelsinki DeclarationDrug AdministrationNew drug applicationsEmission tomographyTumorsInformed consent
2014
Emerging Therapies for Glioblastoma
Thomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging Therapies for Glioblastoma. JAMA Neurology 2014, 71: 1437-1444. PMID: 25244650, DOI: 10.1001/jamaneurol.2014.1701.Peer-Reviewed Original ResearchConceptsClinical trialsCommon primary malignant brain tumorPrimary malignant brain tumorCancer stemlike cellsInnovative clinical trialsBlood-brain barrierMalignant brain tumorsPatient-tailored treatmentNew radiotherapy techniquesHeterogeneous molecular featuresImmune system interactionsGrowth factor receptorTerms glioblastomaMedian survivalDisease courseImmune checkpointsTemozolomide chemotherapyMultimodal treatmentPatient enrollmentAggressive tumorsTreatment advancesBrain neoplasmsDrug exposureBrain microenvironmentMalignant gliomas
2012
Atypical and anaplastic meningiomas treated with bevacizumab
Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. Journal Of Neuro-Oncology 2012, 109: 187-193. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalVascular endothelial growth factor receptorAnaplastic meningiomasRadiographic responseMedian progression-free survivalBest radiographic responseEfficacy of bevacizumabMonths PFS rateEndothelial growth factor receptorKaplan-Meier statisticsActivity of bevacizumabEffective chemotherapeutic optionsAnti-angiogenic agentsTumor blood volumeMR perfusion studiesGrowth factor receptorPFS ratesStable diseaseBevacizumab therapyOverall survivalRANO criteriaRetrospective reviewSurgical optionsProspective studyAggressive tumors